SCNT enjoys widespread support within the medical, research, legal and public communities and among
. SCNT does not require the destruction of human embryos
taken from the uterus and can be conducted with relatively
minimal use of such stem cells and tissues (Elfstrom, 2001,
Elfstrom's (2001) support for ESC use does not, however, preclude the usefulness or viability of voluntarily obtained and provided ASCs. In making a case for expanding the now available stem cell lines obtained from embryonic tissue, Elfstrom argues (2001) that one should consider several reasons in making a decision in favor of this kind of research. First, one must consider the benefits that can be gained with regard to identifying the causes of many diseases and birth defects. Second, when causes are identified, treatments are likely to be forthcoming. This would certainly improve the quality of human life for many people. For example, it would be very important if somatic cell nuclear transfer (SCNT) was instrumental in helping to develop treatment to delay or eliminate the symptoms of Alzheimer's' Disease. What Elfstrom (2001) does not address is the greater ease with which ASCs can be obtained methodologically; these stem cells are not subject to any oversight from governmental regulators as are ESCs. Consequently, even leaving aside any ethical concerns, ASCs may be simply easier to obtain.
Secondly, Elfstrom (2001) makes the case that if SCNT is to be allowed, it is likely that the existing limited number of approved stem cell lines taken from embryonic tissue will soon be not enough to allow for complex research activities. It will be necessary to acquire more stem cell lines, and the way that he thinks is most appropriate is to make use of the "unwanted" embryos that are being held in freezers in fertility clinics that are not going to be used to create new life. He suggests that the current practi...
Embryonic vs. Adult Stem Cells. (2009, July 01). In LotsofEssays.com. Retrieved 10:14, October 31, 2014, from http://www.collegetermpapers.com/viewpaper/1303575007.html